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MaOBJECTIVES This study sought to compare heparin-bonded endografts with femoropopliteal bypass, including quality
of life, using general health and disease-speciﬁc questionnaires as well as patency rates.
BACKGROUND Endovascular treatment continues to advance and is gaining acceptance as primary treatment for long
occlusive or stenotic lesions in the superﬁcial femoral artery. Heparin-bonded expanded polytetraﬂuoroethylene
endografts have been related to outcomes comparable to bypass surgery, but this has not been tested in a randomized
fashion.
METHODS A multicenter randomized-controlled trial was performed comparing femoropopliteal bypass with
heparin-bonded expanded polytetraﬂuoroethylene endografts. Data were analyzed on an intention-to-treat and
per-protocol manner.
RESULTS A total of 129 patients were randomized and 125 patients were treated, 63 in the endoluminal and 62 in the
surgical group (42 venous, 20 prosthetic). Enrollment was terminated before reaching the predeﬁned target number for
patency. Baseline characteristics and anatomical data were similar. Patients were treated for critical limb ischemia in 38.1%
and 32.2% in the endoluminal and surgical arms, respectively. Mean lesion length was 23 cm in both groups and lesions
were largely TransAtlantic Inter-Society Consensus II D. Hospitalization time and 30-day morbidity were signiﬁcantly
lower in the endoluminal group, without differences in serious adverse events (n ¼ 5 each; surgical: 4 venous and 1
polytetraﬂuoroethylene bypass). There were no signiﬁcant differences in Rutherford category between groups at any time
point. At 30 days the endoluminal group showed a greater improvement in quality-of-life scores. At 1 year, these
differences had largely disappeared and no differences in primary (endoluminal: 64.8%; surgical: 63.6%), assisted primary
(endoluminal: 78.1%; surgical: 79.8%), secondary patency (endoluminal: 85.9%; surgical: 83.3%), and target vessel
revascularization (endoluminal: 72.1%; surgical: 71.0%) were observed. Limb salvage rate was 100% in both groups.
CONCLUSIONS Heparin-bonded endoluminal bypass for long segment lesions shows promising results (less morbidity,
faster recovery, and improvement in quality of life with indistinguishable patency rates at 1 year) compared with surgical
bypass. Long-term results have to be awaited. (J Am Coll Cardiol Intv 2017;10:2320–31) © 2017 The Authors. Published
by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).m the aDepartment of Surgery, Rijnstate, Arnhem, the Netherlands; bDepartment of Surgery, Antonius Hospital, Sneek, the
therlands; cDepartment of Vascular Surgery, Isala, Zwolle, the Netherlands; dDepartment of Surgery, Division of Vascular
rgery, University of Groningen, Groningen, the Netherlands; eDepartment of Surgery, Slingeland Hospital, Doetinchem, the
therlands; and the fDepartment of Surgery, Nij Smellinghe Hospital, Drachten, the Netherlands. This is an investigator-
onsored study partly supported by W.L. Gore and Associates. Drs. Reijnen, van Walraven, Fritschy, and Smeets have
eived speaker fees from W.L. Gore and Associates. All other authors have reported that they have no relationships relevant to
contents of this paper to disclose.
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J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 0 , N O . 2 2 , 2 0 1 7 Reijnen et al.
N O V E M B E R 2 7 , 2 0 1 7 : 2 3 2 0 – 3 1 RCT Comparing Endoluminal and Surgical Bypass
2321AB BR E V I A T I O N S
AND ACRONYM S
ABI = ankle-brachial index
CLI = critical limb ischemia
IC = intermittent claudication
PAOD = peripheral arterial
occlusive disease
QoL = quality of life
SF-36 = 36-Item Short Form
Survey
TASC = TransAtlantic Inter-
Society Consensus
WIQ = Walking Impairment
QuestionnaireP eripheral arterial occlusive disease (PAOD) is acommon condition with an increasing preva-lence in an aging population. About 70% of le-
sions are located in the infrainguinal area and about
one-half of interventions for PAOD are performed for
lesions located in the femoropopliteal area (1). For
decades venous femoropopliteal bypass surgery has
been considered to be the gold standard to treat exten-
sive PAOD in the superﬁcial femoral artery. The latest
version of the TransAtlantic Inter-Society Consensus
(TASC) document stated that surgery should be
considered as best option in lesions over 15 cm in
length (2,3). However, endovascular treatment modal-
ities in occlusive and stenotic disease continue to
advance, and they are gaining broader acceptance for
treatment of more complex lesions.SEE PAGE 2332Plain balloon angioplasty is usually reserved for
short lesions only whereas bare nitinol stents have
improved the outcome of endovascular treatment in
intermediate-length lesions (3). More recently, alter-
natives have been introduced, including sirolimus
and paclitaxel drug eluting–based techniques and
covered self-expanding stents. All of them may
improve results of endovascular therapy, especially
in complex lesions. The efﬁcacy of an expanded pol-
ytetraﬂuoroethylene–covered nitinol stent (Viabahn,
W. L. Gore, Flagstaff, Arizona) has been shown in
various case series (4–6). Randomized trials have
already demonstrated their superiority in patency,
without differences in clinical outcome parameters,
over nitinol stents up to 2 years in more complex le-
sions and no differences over a 4-year period
compared with prosthetic, above-the-knee, surgical
bypasses (7,8). The latest generation of this endograft
incorporates several adjustments with potential
clinical beneﬁt, including the integration of the
heparin-bonding technology, improvement of the
proximal edge design, and availability of stent grafts
with a length of 25 cm, reducing the number of
overlap zones. Initial cohort studies have shown
1-year primary patency rates approaching the results
of the historic gold standard: the venous femo-
ropopliteal bypass (6,9).
The current study was designed to compare the
outcomes of the heparin-bonded endograft with the
femoropopliteal bypass, including quality of life
(QoL) and patency rates.
METHODS
The design was a multicenter prospective random-
ized controlled trial comparing heparin-bondedendografts to surgical bypass, on an
intention-to-treat basis, with primary end-
points of 30-day QoL and 1-year primary
patency. The hypothesis of the study was that
treatment with the heparin-bonded endo-
graft would provide a better QoL at 30 days
with equal patency rates at 1 year compared
with surgical bypass.
Patients who met the entry criteria were
included in the study after providing
informed consent. This study was conducted
in accordance with the principles of the
Declaration of Helsinki and Good Clinical
Practice guidelines. The study was approved
by the Medical Ethics committee of Nijmegen
(CMO-2010-089) and the local institutional review
board of each participating center. The design of the
study has been previously published and was regis-
tered at ClincalTrials.gov (NCT01220245) (10).
Patients were recruited from 6 vascular centers in
the Netherlands with a batched randomization with
stratiﬁcation per site. Due to the design the post-
procedural assessment was done in a nonblinded
fashion. An experience of $10 endoluminal bypasses
was required before including patients in the trial to
prevent a learning curve bias. All surgeons had at
least 5 years of experience in both techniques.
Patients were included with long occlusive or stenotic
lesions of the superﬁcial femoral artery with a Ruth-
erford category 3 to 6. Patients with disabling clau-
dication were initially treated with supervised
walking exercise. Cilostazol was not routinely pro-
vided. Cardiovascular risk management was per-
formed according to national guidelines (11).
Patients were screened by duplex ultrasound im-
aging and additional computed tomography angiog-
raphy or magnetic resonance angiography was
performed for procedural planning. Lesions were
categorized according to the TASC II criteria (2,3).
Angiographic and duplex ultrasound assessments
were performed by local treating operators. Cardio-
vascular risk factors were scored according to the
Society for Vascular Surgery and American Associa-
tion of Vascular Surgery medical comorbidity grading
systems (12). Follow-up was performed at 1, 3, 6, 12,
18, and 24 months and annually thereafter until 5
years. This included clinical evaluation; duplex ul-
trasound imaging; ankle-brachial index (ABI)
including standardized walking test if possible; the
36-Item Short Form Survey (SF-36), as a measure
of the general health status in all patients; and the
Walking Impairment Questionnaire (WIQ), as a
measure of disease-speciﬁc health status in patients
with intermittent claudication (IC). The QoL
FIGURE 1 Inclusion Flow Chart
Among the 125 treated patients, 63 were randomized in the endoluminal group and 62 were randomized in the surgical group, of which 42
were treated with a venous conduit. ITT ¼ intention to treat; PP ¼ per protocol.
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2322questionnaires were completed by the patients and
help from a nurse was provided when needed.
The inclusion and exclusion criteria have been
described previously (10).
ENDPOINTS AND DEFINITIONS. The primary
endpoint of the study was QoL at 30 days as assessed
by the SF-36 questionnaire and primary patency at
1-year follow-up. Secondary endpoints included
primary-assisted and secondary patency, morbidity,
clinical improvement, reinterventions, and target
vessel revascularization. Patients with disabling IC
were analyzed separately using patient-reported
pain-free and maximal walking distance and the
WIQ as additional endpoints. Patients with critical
limb ischemia (CLI) were analyzed using major am-
putations as an additional endpoint.
The full list of deﬁnitions and the endovascular
and surgical techniques has been published previ-
ously (10).
Post-procedurally, all patients in both groups were
treated with 80 mg acetylsalicylic acid and 75 mg
clopidogrel daily for the ﬁrst year unless oral anti-
coagulation was indicated for other reasons. After 1
year single antiplatelet therapy (acetylsalicylic) was
continued. All patients started statin before the
intervention.DATA COLLECTION. Data were collected by means of
case report forms and entered in the central online
database with audit trail (“The research manager”,
Deventer, the Netherlands) and controlled by moni-
toring. Data on adverse events during the ﬁrst 30 days
were reported to the data safety data monitoring
board and to the accredited Central Committee on
Research involving Human Subjects. An interim
safety analysis was performed after inclusion of the
ﬁrst 40 patients.
STATISTICAL ANALYSES. Sample size calculation
was performed based on the assumption that the
endoluminal bypass would improve 30-day general
health status, asmeasured by a 10-point increase in the
SF-36 score. With an SD of 20, 63 patients per group
were required (alpha 5%, power 80%). For a non-
inferiority trial with regard to 1-year patency, with an
effect size of 90% and a margin of 10%, 111 patients per
group would be needed (alpha 5%, power 80%). The
effect size of 90% refers to an estimated primary
patency rate at 1 year in the surgical control arm.
To determine which variables followed the
normal distribution, each was tested with the
Kolmogorov-Smirnov test. Data were analyzed based
on an intention-to-treat principle, but additional per-
protocol analyses were performed for patency.





(n ¼ 63) p Value
Age, yrs 66.7  7.9 68.5  8.8 0.227
Male 80.6 73.0 0.312
Cardiovascular risk factors
Tobacco use (current smoker) 51.6 49.2 0.788
Hypertension 74.2 68.3 0.463
Diabetes mellitus 33.9 34.9 0.902
Dyslipidemia 71.0 74.6 0.648
Cardiac disease 38.7 38.1 0.944
Pulmonary disease 27.4 17.5 0.182
Stroke 22.6 14.3 0.231
Renal insufﬁciency 16.1 9.5 0.269
Pre-operative medication
Acetylsalicylic acid 79.0 90.5 0.086
Clopidogrel 8.1 12.9 0.559
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2323Continuous variables are presented as mean  SD or
median (range) if applicable. Differences were tested
using a Student t test (normal distribution) or Mann
Whitney U test (skewed distribution). Categorical
variables are presented as a number followed by
percentage and differences between groups were
tested using chi-square analysis. Analyses of variance
with repeated measures design was used to analyze
changes over time in health status, Rutherford stage,
and ABI. Patency rates are presented as Kaplan-Meier
curves including censoring for patients lost to follow-
up. Differences in survival were tested using the
log-rank test.
A 2-sided p value <0.05 was considered signiﬁcant.
Statistical analyses were performed using SPSS
version 22.0 for Windows (IBM Corporation, Armonk,
New York).Acenocoumarol 14.5 4.8 0.076
Phenprocoumon 1.6 0.0 0.315
Statin 71.7 76.2 0.682
Rutherford classiﬁcation









Values are mean  SD or %.
ASA ¼ American Society of Anesthesiologists.





(n ¼ 63) p Value
TASC II classiﬁcation
B 5.0 3.3 0.458
C 13.3 21.7
D 81.7 75.0
Lesion length, cm 23.6  7.1 23.3  8.3 0.857
Flush occlusion 41.0 28.3 0.182





5.6  1.0 5.2  0.8 0.012
Number of stenosis-free outﬂow vessels




Values are % or mean  SD.
TASC ¼ TransAtlantic Inter-Society Consensus.RESULTS
A total of 131 patients were included in the study, 2 of
whom withdrew informed consent. As a conse-
quence, 129 patients were randomized from
November 2010 to June 2015. Subsequently, another 4
patients were excluded from further analysis
(Figure 1), resulting in 125 treated patients, 63 in the
endoluminal group and 62 in the surgical group. Due
to the low enrollment rate it was decided to terminate
the study after reaching the sample size for the QoL-
endpoint, since the inclusion period would become
unacceptable long. Follow-up compliance at 12
months was 81.1% in the endoluminal group and
88.7% in the surgical group.
BASELINE CHARACTERISTICS. Patient demographics
are depicted in Table 1; there were no signiﬁcant
differences between groups at baseline. In both
groups the proportion of patients treated for IC and
CLI were similar, as was baseline ABI and the pres-
ence of ulcerations.
The anatomical details are shown in Table 2. The
vast majority of patients were treated for TASC II D
lesions without differences between groups except
for larger diameter of the popliteal artery and a higher
proportion of ﬂush occlusions in the surgical group.
At baseline both groups showed equal scores in all
domains of the SF-36, except for a worse “mental
health” domain score in the endoluminal group
compared with the surgical group Table 3) and a
higher score for “health change” in the endoluminal
group compared with the surgical group. No differ-
ences in the separate domains of the WIQ or total WIQ
score were observed between groups in patients with
IC at baseline (Table 4).
TABLE 3 Outcomes of the SF-36 Questionnaire at Baseline and 1-Month and
12-Month Follow-Up, for Both Study Groups








Surgical 42.8 54.3 59.4 0.114 0.055
Endoluminal 43.7 65.8 67.8 <0.001 <0.001
Social functioning
Surgical 67.8 67.2 75.6 0.289 0.952
Endoluminal 66.7 76.5 80.3 0.042 0.060
Role functioning/physical
Surgical 39.2 37.2 67.7 0.440 0.003
Endoluminal 30.3 52.9 67.9 0.003 <0.001
Role functioning/emotional
Surgical 72.4 63.0 84.9 0.183 0.088
Endoluminal 57.7 73.3 78.3 0.045 0.392
Mental health
Surgical 79.1* 76.6 82.5 0.297 0.849
Endoluminal 68.2 79.4 77.4 0.001 0.205
Energy/fatigue
Surgical 62.0 64.8 67.3 0.476 0.861
Endoluminal 57.2 66.9 66.3 <0.001 0.016
Pain
Surgical 47.6 62.7 72.3 0.017 <0.001
Endoluminal 41.5 70.5 74.6 <0.001 <0.001
General health perception
Surgical 54.8 61.3 57.5 0.032 0.865
Endoluminal 57.0 65.7 63.2 0.002 0.045
Health change
Surgical 37.5* 64.1 58.5 <0.001 <0.001
Endoluminal 45.6 64.7 69.7* <0.001 <0.001
Values are %. *p < 0.05 between study groups at the different time points.
SF-36 ¼ 36-Item Short Form Survey.
TABLE 4 Outcomes of the WIQ in Patients With Intermittent Claudication at Baseline and
1-Month and 12-Month Follow-Up, for Both Study Groups








Surgical 20.7 52.5 65.0 <0.001 <0.001
Endoluminal 22.2 67.3 70.2 <0.001 <0.001
Speed
Surgical 29.8 39.3 57.3 0.107 <0.001
Endoluminal 32.0 60.0* 59.9 <0.001 <0.001
Stairs
Surgical 48.1 57.4 64.6* 0.252 0.012
Endoluminal 55.9 77.2* 79.3 <0.001 <0.001
Total WIQ score
Surgical 33.0 47.6 62.3 0.017 <0.001
Endoluminal 36.7 68.5* 67.2 <0.001 <0.001
Values are %. *p < 0.05 between study groups at the different time points.
WIQ ¼ Walking Impairment Questionnaire.
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2324PROCEDURAL DATA. Technical success was ach-
ieved in 93.4% of patients in the endoluminal group
versus 100% in the surgical group (p ¼ 0.039). In the 6
technical failures in the endoluminal group, distal re-
entry was not achieved. Eventually, 4 patients (6.5%)
were crossed over from endoluminal to surgical
bypass. In the surgical group 67.7% of patients
(n ¼ 42) had a suitable vein and the remaining
patients (n ¼ 20) were treated with a prosthetic graft
(all polytetraﬂuoroethylene, except 1 polyester). The
endograft diameters of patients in whom 1 size of
stent grafts was used were 5 mm (n ¼ 4, 7.0%), 6 mm
(n ¼ 32, 56.1%), 7 mm (n ¼ 7, 12.3%), and 8 mm (n ¼ 1,
1.8%). In 13 patients stents with different diameters
were used to cover the lesion, namely 8 mm and 7 mm
(n ¼ 1, 1.8%), 7 mm and 6 mm (n ¼ 7, 12.3%), and 6 mm
and 5 mm (n ¼ 5, 8.8%). In 14 patients only 1 endog-
raft was used (24.6%), 2 endografts were placed in 41
patients (71.9%), and 2 patients needed 3 endografts
to cover the entire lesion (3.5%). Additional endar-
terectomy of the common femoral artery or the
femoral bifurcation was performed in 37.1% of the
endoluminal-treated patients and 21.0% of the
surgical-treated patients (p ¼ 0.048). Other additional
procedures included wound debridement, minor
amputation (n ¼ 2 in the endoluminal group and n ¼ 1
in the surgical group), popliteal angioplasty or
endarterectomy (n ¼ 3 in the endoluminal group
and n ¼ 2 in the surgical group), or infrapopliteal
angioplasty (n ¼ 3 in the endoluminal group only).
Post-procedural ABI signiﬁcantly increased in both
groups from 0.57  0.12 to 0.92  0.16 in the endo-
luminal and from 0.57  0.13 to 0.91  0.18 in the
surgical group (both p < 0.001). Hospital stay was
signiﬁcantly shorter in the endoluminal group (6.0 
4.4 days vs. 3.7  3.4 days; p ¼ 0.002), and less pa-
tients in the endoluminal group needed transfer to
the medium or intensive care unit (not all hospitals
had separated departments).
MORBIDITY AND MORTALITY. The total number of
complications (Table 5) was signiﬁcantly higher in the
surgical bypass group compared with the endolumi-
nal group, as was the 30-day morbidity rate. The vast
majority of complications were minor and resolved
without treatment. In both groups 5 complications
resulted in a procedure-related serious adverse event.
In the endoluminal group 2 dislocated closure
devices resulted in reintervention and 2 patients
were re-admitted for wound infections (treated
with intravenous antibiotics) and another patient’s
hospitalization was prolonged because of pancrea-
titis. In the surgical group these included 1 patient in
whom a reintervention for occlusion was performed,
1 patient with reintervention for occlusion and a deep






Total complications 61 25 0.048
Patients with $1 complication 34 (54.8) 19 (31.1) 0.008
Patients with complication that
resulted in SAE
5 5 0.368
Complications per patient 1 (0–5) 1 (0–3) 0.002
Wound infection 15 4 0.007
Seroma 4 1 0.177
Wound blister 1 0 0.319
Hematoma 7 3 0.196
Rebleeding 3 0 0.082
Luxation of closure device 0 2 0.151
Numbness 10 2 0.016
Edema 16 5 0.009
Neuralgia 1 3 0.301




Congestive heart failure 1 1
Arrhythmia 1 1
Delirium 0 1
Deep venous thrombosis 1 0
Reperfusion pain 0 1
Fever (causa ignota) 1 0
Values are n, n (%), or median (range).
SAE ¼ serious adverse event.
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2325venous thrombosis, 1 patient with neuropathic pain
for which the patient was hospitalized (and treated
with intravenous esketamine hydrochloride), a
patient readmitted for wound infection and treatedFIGURE 2 Evolution of the Rutherford Category
Bar chart presenting the Rutherford stages at baseline as well as 1-mon
bypass.with debridement and intravenous antibiotics, and
another patient readmitted for rebleed treated with
compression, but further complicated by renal func-
tion disorder and hyperkalemia. In addition, there
were no differences in the overall serious adverse
event rate, when including all medical conditions
that required readmission, regardless of whether they
were procedure related. There was no 30-day mor-
tality in either group. At 12 months, 1 patient was
deceased in the endoluminal group due to respiratory
failure and 2 patients in the surgical group, both
related to cancer (p ¼ 0.569).
CLINICAL OUTCOME. ABI signiﬁcantly improved in
both groups after intervention (endoluminal
group: þ0.37  0.03 and surgical group: þ0.35  0.03)
without differences between groups at any time point.
At 30-day follow-up, there was an improvement in
the Rutherford category in 55 patients (93.2%) in the
endoluminal group and 50 patients (92.6%) in the
surgical group (p ¼ 0.992). There were no signiﬁcant
differences in Rutherford category between groups at
any time point (Figure 2). At 1 year both groups
showed a signiﬁcant improvement in Rutherford
category compared with baseline (98.1% and 98.0% of
patients in the endoluminal and surgical groups,
respectively; p ¼ 0.955). At 1 year, over 50% of
patients in both groups were asymptomatic for the
treated leg (65.3% and 58.5% for endoluminal and
surgical groups, respectively). Moreover, none of the
patients showed a deteriorated Rutherford category
compared with baseline. Between 1 and 12 months an
improvement was observed in 19.6% (n ¼ 19) in theth and 12-month follow-up. E ¼ endoluminal bypass; S ¼ surgical
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2326endoluminal group and 10.4% (n ¼ 5) in the surgical
group, and approximately 50% of patients in both
groups did not change in Rutherford category. In the
endoluminal group 28.3% (n ¼ 13) of patients showed
a deterioration in clinical category versus 35.4%
(n ¼ 17) in the surgical group (p ¼ 0.424) between
1 and 12 months.
At baseline, ulcerations were present at the time of
screening in 11 in the endoluminal and 10 patients in
the surgical group, mostly located at the level of the
toes. Ulcerations tended to be larger in the endolu-
minal group (median in both groups was 10 mm, but
the range in the surgical group was 2 to 10, compared
with 2 to 40 in the endoluminal group; p ¼ 0.220).
Four patients had no information available regarding
healing of the ulcer (3 went to another hospital or
withdrew informed consent during follow-up, 1 pa-
tient experienced and eventually died from progres-
sive respiratory failure 4 months after treatment). All
other ulcerations healed with a median time to com-
plete healing of 3.0 months (range: 1.3 to 6.7 months)
in the endoluminal group and 1.8 months (range: 0 to
6.4 months; 1 ulcer was already healed at time of
treatment) in the surgical group (p ¼ 0.144). Minor
amputations were performed during the ﬁrst
3 months only in patients that presented with
Rutherford stage 5 or 6 at baseline (n ¼ 2 in the
endoluminal group and n ¼ 1 in the surgical group).
No major amputations were performed through 1-year
follow-up.
QUALITY OF LIFE. At 1 week the QoL (SF-36) was
signiﬁcantly better in the endoluminal group
compared with the surgical group (50.2 vs. 37.1;
p ¼ 0.011) Overall, WIQ scores, assessed in patients
with IC, were signiﬁcantly better in the endolumi-
nal compared with the surgical group (Table 4). The
endoluminal group showed an earlier improvement
compared with the surgical group. At 1 year, an
improvement in most domains of the SF-36 was
observed in both groups compared with baseline
and no signiﬁcant differences in reported QoL be-
tween groups, except for experienced health
change, in favor of the endoluminal group. At 1
year there was a signiﬁcant improvement in all
domains of the WIQ scores in patients with IC in
both groups compared with baseline, while the
stairs domain remained signiﬁcantly better in the
endoluminal group compared with the surgical
group.
PATENCY RATES AND REINTERVENTIONS. At all
measured time points through 1 year, there were no
signiﬁcant differences in primary, primary-assisted,and secondary patency between groups, based on
the intention-to-treat analyses (Figures 3 to 5). At 12
months the primary, primary-assisted, and secondary
patency for the endoluminal group were 64.8%,
78.1%, and 85.9% and for the surgical group were
63.6%, 79.8%, and 83.3%, respectively. There were
also no differences in the number of reinterventions
performed or time to failure. When we compared
venous bypasses only to the endoluminal bypass,
there were also no signiﬁcant differences in primary
and assisted-primary patency between groups, but
secondary patency rate was better in the endoluminal
group at 6 months only (88.0% vs. 93.9%; p ¼ 0.030).
In 2 of the early failures in the surgical group there
were procedural complications; in 1 patient a
bleeding of the venous conduit occurred during
tunneling and in the other the great saphenous vein
was twisted, leading to immediate failure, which
were treated successfully. Freedom from clinically
driven reintervention at 12 months was 77.0% in the
endoluminal group compared with 70.7% in the sur-
gical group (p ¼ 0.455), based on an intention-to-treat
analysis (Figure 6). Also, no difference was observed
when analyzed per protocol.
At 1 year, a total of 23 reinterventions were per-
formed in 17 patients in the endoluminal group
(27.9%) and 28 reinterventions were performed in 18
patients (29.0%) in the surgical group. Median time to
reintervention was 5.3 months (range: 0.0 to 12.9
months) in the endoluminal versus 3.7 months (range:
0.1 to 11.7 months) in the surgical group (p ¼ 0.666).
DISCUSSION
In the present study we have shown that heparin-
bonded endoluminal bypass is related to a shorter
admission time, a faster improvement in QoL, less
morbidity, and similar patency rates at 1 year when
compared with open surgical bypass in a group of
patients that were treated for long complex femo-
ropopliteal arterial lesions. This is the ﬁrst random-
ized trial that has shown superiority of endovascular
treatment over open surgery with regard to these QoL
features, although these results could be anticipated.
Historically, venous bypass surgery has been consid-
ered the gold standard in terms of long-term patency.
For many patients, however, this may not be worth
the increased morbidity of an open surgical procedure
compared with endovascular methods. Besides, a
suitable vein is not always present. The current study
is relevant to understanding these tradeoffs and an
evaluation of daily practice, including prosthetic
bypasses.
FIGURE 3 Primary Patency for the ITT and PP Analyses
(A) Kaplan-Meier curve presenting the primary patency for the surgical (blue) and endoluminal (green) groups during the 12-month follow-up according to ITT
analyses. (B) Kaplan-Meier curve presenting the primary patency for the surgical (blue) and endoluminal (green) groups during the 12-month follow-up according to
PP analysis. Abbreviations as in Figure 1.
FIGURE 4 Primary-Assisted Patency for the ITT and PP Analyses
(A) Kaplan-Meier curve presenting the primary-assisted patency for the surgical (blue) and endoluminal (green) groups during the 12-month follow-up according to ITT
analyses. (B) Kaplan-Meier curve presenting the primary-assisted patency for the surgical (blue) and endoluminal (green) groups during the 12-month follow-up
according to PP analysis. Abbreviations as in Figure 1.
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FIGURE 5 Secondary Patency for the ITT and PP Analyses
(A) Kaplan-Meier curve presenting the secondary patency for the surgical (blue) and endoluminal (green) groups during the 12-month follow-up according to
ITT analyses. (B) Kaplan Meier curve presenting the secondary patency for the surgical (blue) and endoluminal (green) groups during the 12-month follow-up
according to PP analysis. Abbreviations as in Figure 1.
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considered to be at least as important as the classic
patency parameter and as such the current study is
relevant for the decision-making process in the frail
vascular patients. Although walking distance and QoL
are most appropriate outcome measures for IC,
wound healing and limb salvage are the key issues for
patients with CLI. In patients with CLI wound healing
occurred in all, and the limb salvage rate was 100% in
both groups. This also implies that the potential
overstenting of collateral arteries in the endoluminal
bypass group did not lead to amputations in patients
with an occlusion. This is in accord with a previous
study on the outcome of failed endografts (13). At 30
days, patients in the endoluminal bypass group had a
signiﬁcantly better general and disease-speciﬁc QoL,
as reﬂected by the SF-36 and WIQ scores, whereas
these differences largely disappeared between
1-month and 1-year follow-up. This suggests that the
midterm clinical treatment effect of both techniques
is similar, but that the morbidity of open surgery
delays the improvement. This would advocate an
endovascular ﬁrst strategy also in patients with
extensive disease, particularly because endovascular
treatment does not reduce surgical options afterward.The frailty of the study cohort is reﬂected by the
high morbidity rate, particularly in the surgical arm,
although most complications were minor and did not
require treatment, such as hematoma not requiring
reintervention and edema. Nevertheless, such com-
plications may cause prolonged discomfort for the
patient, although a relation with QoL has not been
found (14). The morbidity rate seems to be higher in
the current study as compared with previous litera-
ture, reporting a morbidity rate of 37% after bypass
surgery (15); the authors, however, clearly demon-
strated thatmorbidity was inconsistently reported and
deﬁnitions were often lacking, which likely caused an
underestimation of the true incidence of complica-
tions after bypass surgery. We are aware that we report
complications more extensively than most reports.
We did not observe differences in patency rates
between groups up to 1-year follow-up. As the study
was terminated before reaching the sample size for
the primary patency endpoint, due to a low inclusion
rate, noninferiority cannot be claimed on this
endpoint. Nevertheless, with the available data there
are no indications that 1 of the arms would become
superior over the other with a larger sample size. The
primary patency rate was lower than anticipated,
FIGURE 6 Freedom From Clinically Driven Reintervention
Kaplan-Meier curve presenting the 12-month freedom from clinically driven reinterven-
tion during the 12-month follow-up according to intention-to-treat analyses. CD-TVR ¼
clinically driven target vessel revascularization.
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endoluminal group are in line with another study
focusing on performance and safety of the 25-cm
Viabahn endoprosthesis for long lesions, with a
1-year primary patency of 67% (9), but they were
lower when compared with the recently published
Japanese trial (6), although comparison with our
study is hampered by the fact that the Japanese reg-
istry consisted of IC patients only with Rutherford
stages 2 and 3 and with lesions mainly classiﬁed as
TASC II type B and C, where the majority of patients
had TASC II type D lesions and over 30% of patients
with CLI. One of their exclusion criteria was unsuc-
cessful pre-dilation of the lesion, which was not the
case in our study. The primary patency in both our
study groups could have been inﬂuenced by our
strictly followed protocol including repeated ultra-
sound investigations, according to the current
standard, and in case of a stenosis with a peak
systolic velocity ratio $2.5 a reintervention was
scheduled, per protocol. This would shift the pri-
mary patency to primary-assisted patency, which
represents freedom from occlusion, and these data
are more in line with the expected rates. Many
studies on femoropopliteal bypass surgery were
performed more than 2 decades ago, in an era where
the assessment of patency was not standardized and
often relied on clinical investigation only. If no
imaging is performed, asymptomatic stenosis could
be missed and consequently not treated, preserving
primary patency.
Technical failure in the endoluminal group was
always due to the inability to pass the lesion. Once
wire access was gained, all devices were successfully
deployed to treat the intended location. Unfortu-
nately, data on the use of dedicated passing and
re-entry devices were not captured in the present
study. With the ongoing improvement of these de-
vices the technical success rate is likely to increase in
the future. It should be noted, that, although it did
not impact technical success, vein with an appro-
priate diameter was available in only 2 of 3 of the
patients randomized to bypass. This has also been
observed in other bypass trials; in the REVAS (Remote
endarterectomy versus supragenicular bypass sur-
gery for long occlusions of the superﬁcial femoral
artery) trial only 45% of patients had a suitable vein
(16). Mandatory preoperative assessment of the vein
with duplex could have increased the number of pa-
tients with a suitable vein, but a potential underes-
timation of the diameter could also have incorrectly
excluded patients. The vast majority of patients weretreated with an endograft $6 mm, and we could not
ﬁnd a relation between the used stent diameter and
outcome, which is in accord with previous studies
(4,17). Interestingly, a concomitant endarterectomy
of the common femoral artery was a predictor for
success in both study arms resulting in better patency
rates compared with those without a concomitant
endarterectomy (data not shown). Although no ste-
notic lesions were present at the location of the
proximal anastomosis or the access site, the state of
atherosclerotic disease in this segment seems to be a
key factor impacting outcomes. Removing calcium
could positively affect local ﬂow patterns in the
inﬂow section. This unexpected observation warrants
further studies focusing on ﬂow and wall shear stress
in this area. New treatment modalities have been
developed, such as drug eluting stents. One of the
ongoing studies is the ZILVERPASS (The Cook Zilver
PTX Drug-eluting Stent Versus Bypass Surgery for the
Treatment of Femoropopliteal TASC C&D Lesions)
study, which has been designed to compare the
endovascular strategy, using drug-eluting stents, and
PERSPECTIVES
WHAT IS KNOWN? Endovascular treatment of
extensive arterial femoropopliteal disease is increas-
ingly being used. Endovascular treatment options are
rapidly expanding and clear treatment algorithms are
lacking. Guidelines still advocate bypass surgery for
long occlusive femoropopliteal lesions.
WHAT IS NEW? The use of heparin-bonded covered
stents is related to fewer complications and faster
recovery compared with bypass surgery. Both tech-
niques have similar outcome at 1-year follow-up in
terms of QoL and patency.
WHAT IS NEXT? Long-term outcomes of this ran-
domized controlled trial have to be awaited. Head-to-
head comparisons with other novel endovascular
techniques, including paclitaxel-based technology,
are needed.
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2330prosthetic bypass surgery in long and more complex
superﬁcial femoral artery lesions (NCT01952457).
STUDY LIMITATIONS. First, the study was termi-
nated after achieving the sample size necessary for
the designed power for the expected QoL, but before
reaching that necessary to determine designed non-
inferiority in patency outcomes. The enrollment rate
during the study period was lower than anticipated
and, given the required sample size for the patency
endpoint, the projected enrollment period would
become unacceptably long. Selection bias might have
occurred. Additionally, the proportion lost to follow-
up was relatively high, reﬂecting the frailty of this
study population. Although the study was performed
in 6 sites, the vast majority of patients were included
in only few of them. This suggests that patients,
meeting the inclusion criteria, were likely to be
missed. Although the power for the primary endpoint
health status was achieved, the absolute numbers in
each group were limited, rendering the subgroup
analyses less reliable. Screen failures were not docu-
mented throughout the inclusion period.
CONCLUSIONS
We have shown that heparin-bonded endoluminal
bypass when compared with the femoropopliteal
bypass, is related to less morbidity, a faster recovery,
and improvement in QoL, whereas no differences in
patency were observed. Although these results are
promising, mid- and long-term results have to beawaited before robust conclusions can be
drawn regarding which technique should be standard
of care.
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